Chronic Myeloid Leukemia
Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.
This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.
Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.
Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.
Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.
1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing 
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.
Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseFebruary 09, 2017
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.
Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).
With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.
During the summer, many patients with CML who are taking oral chemotherapy drugs have questions about taking their drugs while traveling. What advice can we give them regarding this?
Lymphocytosis is associated with higher response rates, significantly longer response durations, and improved overall survival.
Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Sign Up for Free e-newsletters
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers
- Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Hair Dyes and Cancer Risk (Fact Sheet)
- Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning
- Counseling Intervention That Improved CHD is Applied to Cancer Risk in Men
- Low-fat Diet May Improve Overall Survival in Newly Diagnosed Breast Cancer
- Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
- IDDS and SCS: Exploring Multimodal Approaches for Managing Cancer Pain
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|